p. 1−6
2716-9731
Vol.16/No.2
p. 7−16
2716-9731
Vol.16/No.2
p. 17−22
2716-9731
Vol.16/No.2
p. 23−28
2716-9731
Vol.16/No.2
p. 29−36
2716-9731
Vol.16/No.2
p. 37−44
2716-9731
Vol.16/No.2
p. 45−54
2716-9731
Vol.16/No.2
p. 55−62
2716-9731
Vol.16/No.2
p. 63−74
2716-9731
Vol.16/No.2
p. 1−4
2716-9731
Vol.16/No.2
p. 5−12
2716-9731
Vol.16/No.2
p. 13−18
2716-9731
Vol.16/No.2
p. 19−26
2716-9731
Vol.16/No.2
p. 27−34
2716-9731
Vol.16/No.2
p. 35−42
2716-9731
Vol.16/No.2
p. 43−52
2716-9731
Vol.16/No.2
p. 53−60
2716-9731
Vol.16/No.2
+, P < sup>+C+, P < sup>+C- based on ESBLs phenotypic test criteria with 57.15% (n=88), 53.9% (n=83) and 3.25% (n=5) respectively. Isolates that their result became P < sup>+C+ and P < sup>+C- were selected and the Multiplex PCR for them were done. The results of molecular testing showed that 5.7% of isolates, in the other hand 5 strains of E. coli were positive for AmpC β -lactamase. Conclusion: This is the first report of AmpC β -lactamase producing bacteria from Iran. If the type of β -lactamase produced by the pathogen could be detected along with antibiogram before administrating the β -lactamase drug to the patient therapeutic failure might be avoided. Because of significance of these organisms in produce nosocomial infection and in order to prevent them from spread, we need to more study for showing the actual prevalence of them.]]>
p. 61−70
2716-9731
Vol.16/No.2
p. 71−76
2716-9731
Vol.16/No.2
p. 77−83
2716-9731
Vol.16/No.2